Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 2.49M
Average 3.15M
RCKT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Rocket Pharmaceuticals, Inc.NASDAQ: RCKT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $2.15M fell 28.2% year over year, behind the +0.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -28.2% toward the trailing-twelve-month pace of +0.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 11.03M USD
- Year-over-year change
- +17.6%
- 4-year CAGR
- +19.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.03M | +17.6% |
| FY2024 | 2024-12-31 | 9.38M | +32.1% |
| FY2023 | 2023-12-31 | 7.1M | +13.3% |
| FY2022 | 2022-12-31 | 6.27M | +16.6% |
| FY2021 | 2021-12-31 | 5.37M | — |
Depreciation & Amortization vs competitors
How RCKT compares with its peers on the latest reported figures
- RCKT's LTM Mar 2026 depreciation & amortization of $10.18M is the 2nd largest of the 10 companies compared; the peer median is $1.11M.
- Its year-over-year change of +0.4% is the 7th highest of 9, against a peer median of +11.6%.
- Over three fiscal years its annual growth of +20.7% compares with a peer median of +9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.18M | +16.3% | +9.8% | 13.2% | |
| LTM Mar 2026 | $10.18M | +0.4% | +20.7% | — | |
| LTM Mar 2026 | $4.76M | +6.9% | +19.9% | 257.1% | |
| LTM Mar 2026 | $3.14M | +14181.8% | -37.6% | — | |
| LTM Mar 2026 | $2.18M | -186.0% | — | — | |
| LTM Mar 2026 | $2.17M | +0.9% | +0.9% | — | |
| LTM Mar 2026 | $1.11M | -7.9% | -1.4% | — | |
| LTM Mar 2026 | $1.02M | +66.8% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $55K | +44.7% | +18.3% | — | |
| Peer median (excluding RCKT) | $1.11M | +11.6% | +9.8% | 135.1% | |
Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Depreciation & Amortization | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| Deferred Income Tax | 3.15M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 29.24M | 31.01M | 39.41M | 43.92M | 37.06M |
| Change in Working Capital | (3.39M) | 6.08M | 13.46M | 1.92M | (8.3M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.83M) | 9.67M | 0 | 0 | 0 |
| Other Working Capital | 1.44M | (3.6M) | 13.46M | 1.92M | (8.3M) |
| Other Non-Cash Items | 13.53M | 370K | (9.28M) | (6.19M) | (6.68M) |
| Operating Cash Flow | (121.16M) | (178.14M) | (194.92M) | (209.72M) | (190.01M) |
| Capital Expenditures | (7.72M) | (8.62M) | (16.47M) | (5.86M) | (440K) |
| Acquisitions (Net) | 95K | 42.73M | 0 | 0 | 0 |
| Purchases of Investments | (245.88M) | (376.33M) | (390.92M) | (245.89M) | (276.55M) |
| Sales of Investments | 272.44M | 272.89M | 309.33M | 383.45M | 380.76M |
| Other Investing Activities | (95K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 18.85M | (69.33M) | (98.07M) | 131.71M | 103.77M |
| Debt Repayment | 201K | 172K | 139K | 0 | 0 |
| Common Stock Issued | 37.68M | 155.34M | 208.39M | 185.74M | 0 |
| Common Stock Repurchased | 0 | (47K) | 0 | 0 | (67K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (201K) | (172K) | (132K) | 0 | 215K |
| Financing Cash Flow | 37.68M | 155.29M | 208.4M | 185.74M | 148K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (64.63M) | (92.18M) | (84.58M) | 107.72M | (86.1M) |
| Free Cash Flow | (128.88M) | (186.76M) | (211.39M) | (215.59M) | (190.45M) |
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.